Are Fragment C Gamma Receptor (FCGR) Germline Polymorphisms Predictive Biomarkers in Metastatic Colorectal Cancer?

Formica V*, Cereda V, Nardecchia A, Morelli C, Lucchetti J and Roselli M

Medical Oncology Unit, ‘Tor Vergata’ Clinical Center, University of Rome, Italy

Abstract

The treatment of metastatic colorectal cancer has undergone significant improvements over the last decade with the introduction of molecularly targeted monoclonal antibodies (mAbs). Among these, cetuximab, a chimeric IgG1 antibody directed against the extracellular domain of EGFR, has demonstrated a survival benefit for KRAS wild type (WT) tumors. Even though KRAS genotyping has significantly refined patient selection allowing an increase in tumor radiological response from 25% of the whole metastatic colorectal cancer (MCRC) population to 45% of the KRAS-WT subset, still for a significant proportion of patients anti-EGFR mAbs will be ineffective, thus resulting in unnecessary toxicity and cost.

Polymorphisms of Fragment C gamma receptor (FCGR) gene have the potential for being used as predictive biomarkers of cetuximab activity since part of this drug’s tumoricidal effect is immune-mediated via FcγR-triggered ADCC (antibody-dependent cellular cytotoxicity). The aim of the present review is to summarize available data on the predictive/prognostic value of FCGR polymorphisms for cetuximab-treated MCRC patients and to discuss possible future directions in this area of research.

Keywords: Mccrc, Cetuximab; Anticancer mabs

Introduction

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide [1]. When metastatic (MCRC), it is largely incurable and palliative chemotherapy represents the treatment of choice. Recently introduced monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) have produced substantial improvements in MCRC clinical outcome with a prolongation of median survival from 12 to 22-24 months [2].

Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti-EGFR monoclonal antibody (mAb), has been proven effective in MCRC without mutations in the downstream molecules of EGFR pathway such as KRAS.

However, even in the KRAS wild type enriched population, cetuximab produces, in combination with standard chemotherapy, a tumor overall response rate (ORR) ranging from 35-45% in the first-line setting.

Moreover, the action of this drug seems to be exerted beyond the mere interference with EGFR-related growth signal on cancer cell. Indeed, responses to cetuximab are also observed for tumors with constitutively activated EGFR pathway secondary to KRAS mutation. In particular, De Roock et al. [3] found in in vitro and in vivo mouse models that KRAS-G13D-mutated colorectal cancer cells were similarly killed by cetuximab as were KRAS wild-type cells. They confirmed this finding in the clinical setting by showing, in a pooled analysis of several randomized trials, a survival gain from the addition of cetuximab in patients carrying the KRAS-G13D tumor mutation.

Therefore, further reliable and predictive biomarkers are needed to more accurately select patients responsive to cetuximab and minimize unwanted toxicity and costs.

Since part of cetuximab activity is immune-mediated via activation of effector cell receptors binding the immunoglobulin fragment C (Fc), functional polymorphisms (single nucleotide polymorphisms, SNPs) of fragment c-γ receptors (FCGR2A and FCGR3A) are ideal candidate as predictive biomarkers. Moreover, the immune-mediated antitumor activity of cetuximab might also justify the benefit seen for some KRAS mutated tumors.

The immune response triggered by cetuximab via FcγR activation is defined Antibody dependent cellular cytotoxicity (ADCC). It relies on the bifunctional property of the IgG1 which can form a bridge by binding the EGFR expressed on tumor cell surface (with the idiotype moiety) and, at the same time, the FcγRs on immune cells (such as Natural Killer cells, Macrophages, Antigen Presenting Cells). The tumor cell-IgG1-FcγR interaction triggers the lytic attack or phagocytosis of tumor target cells by immune effector cells.

Three classes of closely related FcγR have been identified (FcγR1/CD64, FcγR2/CD32 and FcγR3/CD16) that are differentially encoded by a set of 10 genes located on chromosome 1 with high sequence homology (FCGR1A, FCGR1B, FCGR1C; FCGR2A, FCGR2B1, FCGR2B2, FCGR2B3, FCGR2C; FCGR3A and FCGR3B) [4]. Functional single nucleotide polymorphisms (SNPs) have been identified at position 131 of FCGR2A and at position 158 of FCGR3A which determine a substitution from histidine to arginine (H131R) and from valine to phenylalanine (F158V), respectively. In particular the FcγRIIIa 158 V has been demonstrated to possess a higher affinity for the IgG1 Fc and to induce an increased ADCC of cetuximab-coated tumor cells [5], while its expression level remains unchanged [6].
Apart from cetuximab, the influence of ADCC has also been observed with other widely used monoclonal antibodies (mAbs) targeting surface cancer antigens, such as rituximab and trastuzumab. The aim of the present review is to briefly review the current knowledge on the influence of ADCC and FCGR polymorphisms for the most commonest targeting surface cancer antigens, such as rituximab and trastuzumab.

**FCGR SNPs and Commonly used Anticancer Mabs**

ADCC has been identified as an effective immune-based mode of action for therapeutic mAbs of IgG1 class, as Fcγ receptors display the highest affinity for this class of molecules and less or even absent binding to immunoglobulins of the IgG2 isotype.

Currently, the anti-CD20 rituximab, the anti-HER2 trastuzumab and the anti-EGFR cetuximab are IgG1 mAbs approved and widely used for B cell lymphomas and leukemias, HER2-positive breast and gastric cancer, and for head and neck and KRAS wild-type colorectal carcinomas, respectively. Rituximab and trastuzumab were initially investigated for differential activity on the basis of functional polymorphisms of FCGRs.

The possible influence of FCGR SNPs on trastuzumab efficacy was initially documented in two small retrospective series including, collectively, 89 metastatic and 15 locally advanced breast cancer patients. It was observed that FCGR-131 H/H and FCGR-158 V/V genotypes were associated with increased radiological response, pathological response and progression-free survival [7,8]. However, Hurvits et al. reviewed the FCGR genotypes in nearly 1200 patients enrolled in the BCIRG-006 phase III adjuvant trial, and found neither a prognostic nor a predictive role for FCGR SNPs as any disease free survival differences were noted according to different FCGR alleles, both in the trastuzumab and chemotherapy-only arm [9].

A number of retrospective studies including rituximab monotherapy in follicular lymphoma patients have shown an association between FCGR-158 V/V genotype and increased response to therapy. In particular, in a series of 49 patient’s complete response of two months were 100% for FCGR-158 V/V and 68% for the other genotypes [10]. In another cohort of 87 patients, progression free survival at 2 years was 45%, 12% and 16% for FCGR-158 V/V, V/F and F/F patients, respectively [11]. However in the larger analysis of follicular lymphoma patients included in the PRIMA trial (n=460), a phase III randomized study exploring the role of rituximab maintenance after induction chemoimmunotherapy, no influence of FCGR polymorphisms was observed on progression-free survival (PFS), whilst FCGR-158 V/V genotype was associated with increased grade 3-4 neutropenia [12].

**FCGR SNPs and Cetuximab in Mcrc Patients**

**Methods**

We searched pubmed for “cetuximab”, “fragment c gamma receptor polymorphisms” and “colorectal cancer” key terms, relevant retrieved articles were scanned in their reference lists for additional studies of interest.

As of August 2013, we identified 12 retrospective studies exploring the predictive/prognostic role of FCGR polymorphisms in cetuximab-treated MCRC patients (Table 1).

**Results**

There is still wide uncertainty on what extent cetuximab immune effects add to the functional inhibition of EGFR activation accomplished by this drug. Further complexity derives from the usual combination regimens applied for cetuximab as it is often administered in addition to the chemotherapeutic drugs fluorouracil, irinotecan or oxaliplatin. It has been documented that chemotherapy may alter EGFR expression on cancer cells. Having ascertained the functional effect of FCGR SNPs on ADCC, it remains to clarify on what extent they could be prognostic as determinants of a general antitumor immune response independent of cetuximab activity or rather predictive biomarker specific for cetuximab action.

Moreover, the concomitant administration of chemotherapy may significantly influence cetuximab-related ADCC, as it can either increase tumor antigen shedding (and hence adoptive immune response) via direct cancer cell killing or restrain immunostimulatory pathways because of its myelotoxic side effects.

Finally, the timing of cetuximab-driven immune reaction is still to be elucidated, as this could substantially influence the type of clinical endpoint that is most affected. An ‘acute’ effect of this immune reaction would mostly increase the radiological response rate whilst a chronic effect of immune-protection (vaccine-like) ‘in the long run’ would translate in survival advantage (PFS or OS). In the latter case, significant results would not be expected if FCGR SNPs were analysed in the third line setting of treatment where patient lifespan is anticipated to be relatively short.

Therefore, to unravel whether the line or combination of therapy would influence the predictive role of FCGR SNPs, in the present review retrieved data are classified according to the association or not with chemotherapy and the administration as first or subsequent line of treatment.

**FCGR Polymorphisms and Single Agent Cetuximab**

Zhang et al. were the first to report a possible influence of FCGR polymorphisms on cetuximab activity in colorectal cancer [13]. They evaluated the effect of FCGR2A-H131R and FCGR3A-F158V alleles in a sample of 39 subjects derived from the larger phase II single-arm trial of cetuximab monotherapy in heavily pre-treated EGFR-expressing MCRC patients [14]. To the best of our knowledge, this is the only published study reporting on FCGR polymorphisms in MCRC treated with cetuximab monotherapy.

The subgroup selected for FCGR analysis was considered adequately representative of the whole trial population as no differences in outcome were noted between the two patient cohorts (approximately, median progression free survival (PFS) 2 months and median overall survival (OS) 6 months for both). Authors found a shorter PFS for patients carrying the FCGR2A-H131R or FCGR3A-F158V genotype, Relative Risk 1.43 and 2.28, p values 0.037 and 0.055, respectively, thus stating that the two polymorphisms were independently associated with PFS. However the most significant difference was found for patients in whom the contemporary presence of at least one H and one F allele occurred, suggesting a possible functional interaction between the two receptors (stratified Relative Risk for PFS for patients with either R/R or V/V: 5.37, 95% CI 1.92-15.0, p=0.001). Moreover, Relative Risk for R/R and V/V genotypes evaluated singularly had 95% Confidence Intervals that crossed the unity, indicating a weak statistical significance when the two genes are considered separately. Finally tumor response to treatment was observed only in two cases making it difficult to discern a possible predictive value of the polymorphisms in addition to the prognostic effect of H+F allele combination. KRAS mutational status was not available.
Table 1: Main characteristics of retrieved retrospective studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>related clinical trial</th>
<th>N. of patients</th>
<th>Type of cetuximab treatment</th>
<th>line of therapy</th>
<th>main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang et al.</td>
<td>[13] phase II (ImClone 0144)</td>
<td>39</td>
<td>cetuximab monotherapy</td>
<td>3rd line</td>
<td>Shorter PFS for patients with FCGR2A R/R or FCGR3A V/V</td>
</tr>
<tr>
<td>Bibeau et al.</td>
<td>[19] None</td>
<td>69</td>
<td>cetuximab + irinotecan</td>
<td>3rd line</td>
<td>PFS advantage for FCGR3A V/V</td>
</tr>
<tr>
<td>Calemma et al.</td>
<td>[20] None</td>
<td>49</td>
<td>cetuximab + various chemotherapy</td>
<td>1st, 2nd and 3rd line</td>
<td>Response Rate and PFS advantage for FCGR3A V/V</td>
</tr>
<tr>
<td>Rodriguez et al.</td>
<td>[21] None</td>
<td>44</td>
<td>cetuximab+various chemotherapy</td>
<td>1st, 2nd and 3rd line</td>
<td>higher percentage of patients progressing within 6 months in the FCGR2A R/R and FCGR3A F/F groups</td>
</tr>
<tr>
<td>Etienne-Grimaldi et al. [15]</td>
<td>phase II (CETUFTIRI)</td>
<td>51</td>
<td>cetuximab + UFT + irinotecan</td>
<td>1st line</td>
<td>Shorter OS for FCGR3A F/F</td>
</tr>
<tr>
<td>Park et al.</td>
<td>[22] None</td>
<td>107</td>
<td>cetuximab+irinotecan</td>
<td>3rd line</td>
<td>no significant association of FCGR SNPs with outcome</td>
</tr>
<tr>
<td>Dahan et al.</td>
<td>[23] None</td>
<td>56</td>
<td>cetuximab+various chemotherapy</td>
<td>1st, 2nd and 3rd line</td>
<td>Shorter OS for FCGR3A V/V</td>
</tr>
<tr>
<td>Zhang et al.</td>
<td>[24] phase II (BOND-2)</td>
<td>65</td>
<td>cetuximab + bevacizumab + irinotecan</td>
<td>3rd line</td>
<td>Increased response for FCGR3A F/F only in cetuximab + bevacizumab treated patients</td>
</tr>
<tr>
<td>Paez et al.</td>
<td>[25] None</td>
<td>104</td>
<td>cetuximab + various chemotherapy</td>
<td>1st, 2nd and 3rd line</td>
<td>no significant association of FCGR SNPs with outcome</td>
</tr>
<tr>
<td>Pander et al.</td>
<td>[16] phase III (CAIRO-2)</td>
<td>122</td>
<td>cetuximab + oxaliplatin + capectabine + bevacizumab</td>
<td>1st line</td>
<td>PFS advantage for FCGR3A F/F</td>
</tr>
<tr>
<td>Graziano et al.</td>
<td>[27] None</td>
<td>110</td>
<td>cetuximab + irinotecan</td>
<td>3rd line</td>
<td>no significant association of FCGR SNPs with outcome</td>
</tr>
<tr>
<td>Negri et al.</td>
<td>[28] None</td>
<td>86</td>
<td>cetuximab + various chemotherapy</td>
<td>1st, 2nd and 3rd line</td>
<td>no significant association of FCGR SNPs with outcome</td>
</tr>
</tbody>
</table>

Abbreviation: PFS: progression Free Survival; OS: Overall Survival; SNPs: Single Nucleotide Polymorphisms

FCGR Polymorphisms and Cetuximab+Chemotherapy Combination in the First-line Setting

Two studies reported the effect of FCGR polymorphisms in MCRC patients treated with firstline cetuximab+chemotherapy.

In an ancillary study of the firstline phase II CETUFTIRI (cetuximab+tegafur-uracil+irinotecan) trial, including chemoaneat metastatic patients with no KRAS selection, both FCGR2A-131 and FCGR3A-158 SNPs were evaluated. Patients with FCGR3A-158 V/F or V/V genotype have significantly longer survival compared with FCGR3A-158 F/F patients (Median overall survival 20.9 months (20 patients and 18 deaths) vs. 12.4 months (31 patients and 23 deaths), respectively, Log rank test: P=0.032) [15].

Pander et al. reported the largest dataset regarding the impact of FCGR polymorphisms on outcome of cetuximab-treated MCRC patients. Included participants were from the large phase III trial, CAIRO-2, randomizing KRAS wild type chemo-naive patients to either capecitabine+oxalipaltin+bevacizumab or the same+cetuximab. In the cetuximab treated arm, making this feature truly predictive of cetuximab effect. Surprisingly, the F variant produces a weaker binding of Fc gamma receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

This is the only study derived from a large phase III trial and including a no-cetuximab control arm. FCGR3A-158 F/F genotype was found to correlate with a significantly longer PFS only in the cetuximab-treated arm, making this feature truly predictive of cetuximab effect. Surprisingly, the F variant produces a weaker binding of Fc gamma receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].

Pander motivated this apparent incongruity by speculating that a poor IIIA receptor to IgG1 antibodies resulting in reduced ADCC [17].
rather than predictive, of this polymorphism. In further confirmation of that, the PFS advantage was seen for both wild type and mutant KRAS tumors [19].

In another dataset by Calemma et al., 49 KRAS wild-type MCRC patients were treated with different combinations of chemotherapy+cetuximab (or the other approved anti-EGFR MAb panitumumab) and at different phases of the disease (7 cases as first-line, 42 cases as subsequent line of treatment). Authors found a significant correlation of FCGR-158V allele with both tumor radiologic response (43% v 20%, for V/V or V/F genotype vs F/F genotype, respectively, p=0.035) and median PFS (18 vs. 9 months, respectively, p=0.04) [20].

Another retrospective analysis by Rodriguez et al. [21] evaluated FCGR polymorphisms in 44 patients treated with cetuximab-standard chemotherapy in first or subsequent lines of therapy. Only patients with mutation in genes involved in the downstream pathway of EGFR (namely KRAS, NRAS, BRAF or PI3K) were included. Results of note were the high percentage of early progressing patients (<6 months) within the group of FCGR2A-131 R/R genotype (83%, p=0.017) and within the FCGR3A-158 F/F group (77%, p=0.008).

In another cohort of 107 irinotecan-refractory patients published by Park et al., no significant correlation with outcome (ORR, PFS or OS) was found for both FCGR2A-131 and FCGR3A-158 polymorphisms [22]. No response was observed in the four patients with FCGR2A R/R genotype, whilst ORR was 24% and 39% for FCGR2A H/H ed H/R patients, respectively, but p value was not significant (p=0.08), presumably for the limited sample size.

In a retrospective analysis by Dahan et al., 56 patients treated in the majority of cases with cetuximab + irinotecan (71%) and in the third line setting (55%) were genotyped for both FCGR2A-131 and FCGR3A-158 loci. FCGR3A-158 V/V was carried by 9 patients and conferred a statistically significant worse prognosis (Median survival 9.8 months in F/F patients, 29 patients, 21 events vs. 9.0 months in F/V patients, 20 patients, 15 events vs. 2.6 months in V/V patients, 6 patients, 6 events; Log Rank test: p=0.001) [23].

Still from the group of Zhang et al., a subgroup of patients (n=65) included in the BOND-2 phase II trial were genotyped for several candidate genes involved in EGFR signalling pathway, ADCP, angiogenesis or drug-detoxification pathway. In the BOND-2 study, both wild-type and mutated KRAS patients, heavily-pretreated, were randomized to either cetuximab+bevacizumab (CB) or cetuximab + bevacizumab+irinotecan (CBI). FCGR3A-158 polymorphism was significantly associated with response rate in the CB arm (n=34), with a 56% response rate for the F/F genotype compared to 8% for V/V, p=0.054 [24].

Paez et al. included 104 patients treated with cetuximab (or panitumumab) + chemotherapy, in a retrospective study exploring the impact of clinical factors, skin toxicity, KRAS and FCGR genotypes on response rate (ORR) and progression free survival (PFS). Most of patients received cetuximab+irinotecan (69%) as second or third line of therapy (88%). They found no significant difference on clinical outcome across FCGR genotypes; in particular ORRs were 17% and 41% for FCGR2A-131 H/H and R/R and 27% and 22% for FCGR3A-158 V/V and F/F, respectively, p=0.13 and 0.5. Median PFS was 4 vs. 6 and 4 vs. 7 months, respectively, p=0.61 and 0.5 [25].

Finally, Negri et al. first demonstrated in vitro the enhanced ADCC mediated by peripheral blood mononuclear cells (PBMCs) of MCRC patients carrying the FCGR-158 V/V genotype; then they tried to translate in vitro findings into the clinical setting by correlating both FCGR2A and FCGR3A SNPs with ORR, PFS and OS. By using the EGFR-expressing LoVo colorectal cancer cell line and a Chromium-51 release assay, they found that PBMCs expressing the FCGR-158 V/V genotype lead to a two-fold increase in ADCC-mediated LoVo cell killing. However, this did not translate in increased clinical efficacy of cetuximab as no ORR, PFS or OS difference was observed for FCGR-158 V/V vs. F/F in 86 patients treated with cetuximab plus either irinotecan- or oxaliplatin-based chemotherapy, in both first-line and subsequent lines of therapy (ORR 16% vs. 26%, p=0.68, median PFS 3.1 vs. 4.6 months, p=0.18, median OS 9 vs. 13 months, p=0.16) [26].

FCGR were also assessed by Graziano et al. in a cohort of 110 patients treated with cetuximab+irinotecan in the third-line setting. Results were not explicitly reported, though it is presumable that no significant influence was found in terms of clinical outcome [27].

Meta-Analysis of Tumor Response Rate and FCGR3A 158 Genotype

Data on response rate by FCGR3A-158 genotype were reported in nine out of 12 retrieved studies and were meta-analysed to evaluate whether a definitive association between F/F or V/V genotype and cetuximab activity could be found (Table 2).

Altogether, a higher response rate was observed in presence of a V allele (29% vs. 27%) with a 8% increased probability of response for the F/V or V/V genotype, but this was not statistically significant: Total Odds Ratio (random effects) 1.08 (95% Confidence Interval 0.60-1.96) (Table 2 and Figure 1).

Conclusion

We found 12 retrospective studies exploring the possible prognostic/predictive role of FCGR polymorphisms on outcome of cetuximab-treated MCRC patient. Results were clearly conflicting and our attempted meta-analysis looking at tumor response failed to reach significant results. We focused on response rate, rather than progression free or overall survival, because it is an outcome measure related more to the drug activity than to the inherent tumor aggressiveness and prognosis. Apart from one study, all reported cohorts of patients were cetuximab-treated with no control arm and a significant impact of a variable on PFS or OS in single arm studies keeps open the question as to whether it represents a prognostic rather than predictive factor.

Contradictory results may be largely explained by the inter- and intra-study variety of chemotherapy combinations and phases of the disease, with treatments delivered as first, second, third and even forth line of therapy.

In particular, the pure effect of cetuximab (monotherapy) on ADCC, where no interference of chemotherapy is possible, has been investigated only in one study with a relatively small sample size, moreover only in two studies cetuximab was delivered in the first-line setting allowing acceptable observation on the effect of ADCC on survival outcome 'in the long run'.

The only study derived from a large phase III trial and including a no-cetuximab control arm was that by Pander et al, where KRAS-wild type patients with the FCGR3A 158 F/F genotype had a significantly longer PFS only in the cetuximab-treated arm, making this feature truly predictive of cetuximab effect. Surprisingly, the F variant produces a weaker binding of Fc gamma IIIA receptor to IgG1 antibodies resulting in reduced ADCC [28]. Pander motivated this apparent incongruity...
by speculating that a poor FcγR/IgG1 binding may also result in a reduced activation of tumor associated macrophages (TAMs) which facilitate tumor progression by releasing pro-angiogenic factors such as IL-8, IL-10 and VEGF [16]. This was confirmed by the same authors in in vitro tests. Authors justified with an enhanced M2 cetuximab-induced activation the failure of the phase III randomized CAIRO-2 trial aiming at improving outcome with the addition of cetuximab to the standard capcitabine+oxaliplatin+bevacizumab regimen [29]. In light of Pander findings, the way forward to optimize cetuximab combination would be, first of all, to extensively study in preclinical models the balance between M2 and ADCC activation. As an example, a robust engineered model of mouse expressing the human Fc-gamma-receptors is still lacking to fully explore immune effects of cetuximab. Such a model would be desirable also in order to evaluate the right sequence and combination with chemotherapy, since some chemotherapeutic agents may alter EGFR expression on cancer cells and macrophages and hence condition ADCC activation [30,31].

In conclusion FCGR genotyping, though it carries the potential for being an attractive predictive test of cetuximab activity, exploring the probability that an immune-mediated antitumor response is elicited, has clearly shown contradictory clinical results for MCRC patients. We think that such a wide inconsistency in research outcome may be largely explained by the study heterogeneity including different lines of therapy and different combination regimens. Currently FCGR polymorphisms cannot be considered reliable predictive biomarkers of cetuximab response and therefore it appears inappropriate to deny this drug on the basis of FCGR genotype. Furthermore, as the other side of the coin is the eventuality that genotypes enhancing ADCC may induce pro-inflammatory pro-tumorigenic macrophage activation, their role should be investigated prospectively in randomized trial and substantiate with the functional assessment of both immune and inflammatory responses.

### Table 2: FCGR3A-158 genotype and tumour response rate in 9 retrospective studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>N. of responding patients with F/F genotype</th>
<th>Total n. of patients with F/F genotype</th>
<th>N. of responding patients with F/V or V/V genotype</th>
<th>Total n. of patients with F/V or V/V genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calemma et al. [20]</td>
<td>1</td>
<td>4</td>
<td>19</td>
<td>44</td>
</tr>
<tr>
<td>Bibeau et al. [19]</td>
<td>2</td>
<td>15</td>
<td>9</td>
<td>53</td>
</tr>
<tr>
<td>Zhang et al. [13]</td>
<td>2</td>
<td>18</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>Rodriguez et al. [21]</td>
<td>3</td>
<td>13</td>
<td>16</td>
<td>31</td>
</tr>
<tr>
<td>Etienne-Grimaldi et al. [15]</td>
<td>5</td>
<td>20</td>
<td>19</td>
<td>31</td>
</tr>
<tr>
<td>Zhang et al. (2010) [24]</td>
<td>9</td>
<td>21</td>
<td>12</td>
<td>44</td>
</tr>
<tr>
<td>Negri et al. [26]</td>
<td>7</td>
<td>27</td>
<td>13</td>
<td>59</td>
</tr>
<tr>
<td>Park et al. [22]</td>
<td>14</td>
<td>36</td>
<td>18</td>
<td>71</td>
</tr>
<tr>
<td>Paez et al. [25]</td>
<td>10</td>
<td>48</td>
<td>11</td>
<td>53</td>
</tr>
<tr>
<td>TOTAL</td>
<td>53</td>
<td>198</td>
<td>117</td>
<td>405</td>
</tr>
</tbody>
</table>

**Overall Response Rate**

27% 29%
References